Evidence map›Paper›PMID 42351938›Full record

ReviewBioengineering (Basel, Switzerland)2026

Advances and Prospects in MOF-Based Platforms for Tumor Hyperthermia.

Diyi Feng, Liqin Ge

Abstract readReview
In one paragraph

Review in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Diyi FengState Key Laboratory of Digital Medicine Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing 211189, China.
Liqin GeState Key Laboratory of Digital Medicine Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing 211189, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metal-organic framework (MOF)-based materials have become promising platforms for tumor hyperthermia by integrating energy conversion, tumor microenvironment regulation, and multimodal therapy within programmable porous structures. This review summarizes recent advances in intrinsic MOFs, MOF composites, and MOF-derived materials for photothermal therapy, microwave hyperthermia, and magnetic hyperthermia. The reviewed studies show that high-valence metal MOFs mainly provide stable and modifiable frameworks, whereas transition-metal, magnetic, and multimetallic MOFs contribute to redox regulation, ROS generation, magnetic response, and microwave energy dissipation. Beyond localized heat generation, MOF-based platforms enhance therapeutic efficacy by combining hyperthermia with chemotherapy, chemodynamic therapy, metabolic intervention, immunotherapy, and imaging guidance. These integrated strategies help overcome incomplete ablation, thermotolerance, oxidative stress resistance, and tumor recurrence. However, clinical translation is still limited by insufficient standardization, uncertain degradation behavior, metal-ion safety, and inadequate thermal dose control. Future development should emphasize mechanism-oriented design, controllable composition, long-term biosafety, and image-guided thermal regulation to advance MOF-based hyperthermia toward precise and clinically relevant cancer therapy.

Indexed as

combination therapymagnetic hyperthermiamicrowave hyperthermiaMOFsphotothermal therapytumor hyperthermia

Identifiers

PMID42351938
PMCPMC13295309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.